score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Inferential		Clinical evidence	Copy Number	CCND1	Amplification				0.0	0.0		Putatively Actionable	Palbociclib	CDK4/6 inhibition	Targeted therapy	CCND1 amplification was observed in a study of 109 microdissected pancreatic adenocarcinoma tumors, and is predicted to have antitumor effects in response to palbociclib.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744								Putatively Actionable	0.0	CCND1 amplification showed reduced recurrence-free survival in a randomized control trial of postmenopausal breast cancer patients.	"Bostner, Josefine, et al. ""Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer."" Oncogene 26.49 (2007): 6997-7005."	https://doi.org/10.1038/sj.onc.1210506	0				CCND1 Amplification	1.0	PROS01448-1115161	PROS01448-1115161-Tumor-SM-5SGU1	
Putatively Actionable		Clinical evidence		Somatic Variant	AR	Missense	p.T878A	0.4224	232.0	0.0	0.0									Putatively Actionable	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220						0	290.0	0.4759	1.0	AR p.T878A (Missense)		PROS01448-1115161	PROS01448-1115161-Tumor-SM-5SGU1	PROS01448-1115161-Normal-SM-6CAJL
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.D918G	0.434	106.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf													0	29.0	0.5172	0.9995	CDK12 p.D918G (Missense)	0.0	PROS01448-1115161	PROS01448-1115161-Tumor-SM-5SGU1	PROS01448-1115161-Normal-SM-6CAJL
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.R858W	0.3821	123.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf													0	40.0	0.5	0.9999	CDK12 p.R858W (Missense)	0.0	PROS01448-1115161	PROS01448-1115161-Tumor-SM-5SGU1	PROS01448-1115161-Normal-SM-6CAJL
Investigate Actionability	Preclinical			Copy Number	FGFR1	Deletion				0.0	0.0		Investigate Actionability	Infigratinib	FGFR inhibition	Targeted therapy	A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.	Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33.	https://doi.org/10.1158/2159-8290.CD-12-0210													0				FGFR1 Deletion		PROS01448-1115161	PROS01448-1115161-Tumor-SM-5SGU1	
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.K335I	0.3082	292.0	0.0	0.0																Investigate Actionability	1.0	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324	0	167.0	0.2515	1.0	CTNNB1 p.K335I (Missense)		PROS01448-1115161	PROS01448-1115161-Tumor-SM-5SGU1	PROS01448-1115161-Normal-SM-6CAJL
Investigate Actionability			Clinical evidence	Copy Number	ESR1	Deletion				0.0	0.0																Investigate Actionability	0.0	Ampifications of ESR1 was significantly associated with poor disease-free survival and overall survival in a study of 99 patients with ER-positive breast cancer tumors.	Nielsen KV, Ejlertsen B, Muller S, et al. Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Res Treat. 2011;127(2):345-55.	https://doi.org/10.1007/s10549-010-0984-y	0				ESR1 Deletion		PROS01448-1115161	PROS01448-1115161-Tumor-SM-5SGU1	
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.P334A	0.2516	159.0	0.0	0.0																					0	81.0	0.3086	1.0	ESRP1 p.P334A (Missense)		PROS01448-1115161	PROS01448-1115161-Tumor-SM-5SGU1	PROS01448-1115161-Normal-SM-6CAJL
Biologically Relevant				Copy Number	MC1R	Deletion				0.0	0.0																					0				MC1R Deletion		PROS01448-1115161	PROS01448-1115161-Tumor-SM-5SGU1	
Biologically Relevant				Copy Number	GATA3	Deletion				0.0	0.0																					0				GATA3 Deletion		PROS01448-1115161	PROS01448-1115161-Tumor-SM-5SGU1	
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.396																									0				COSMIC Signature (version 2) 1 (40%)		PROS01448-1115161		
